Cambridge Healthtech Institute第5届

Adoptive T Cell Therapy 2: Development

( 过继T细胞免疫疗法2:开发 )

2018年8月30日~31日


本单元以过继T细胞疗法药物的开发为主题,聚焦于利用嵌合抗原受体(CAR)、T细胞受体(TCR)、肿瘤内浸润淋巴球(TIL)的疗法实用化方面之必要步骤。临床研究的进展、个案研究、在使过继T细胞疗法能有效发挥功能上具备重要意义的要素等议题也将被包含在内。

Coverage will include, but is not limited to:

  • What's New in Adoptive Cell Therapy
    • New developments: Leapfrogging to commercialization
    • New tools: Next-gen CAR designs, gene editing, off-the-shelf cells
    • Emerging targets: Tumor-specific mutations
  • Autologous Immune Cell Products
  • Adoptive Cell Therapy Using Non-Genetically Manipulated Lymphocytes
    • Improving and extending T cell therapies to target tumor-specific mutation
  • Adoptive Cell Therapy Using Chimeric Antigen Receptors (CAR) and T Cell Receptors (TCR)
    • Increasing T cell potency and persistence
    • Creating more controllable T cells
    • Moving towards treatment of solid malignancies
    • Clinical trial updates
  • Allogeneic Immune Cell Products
    • New platform technologies
    • Preclinical data and clinical studies

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English





免费电子邮件通知服务